What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

In a conversation with Pharmaceutical Executive, James LaValle, Chair of the International Peptide Society, chief science officer, Life Time, discussed the fallout from the FDA's Pharmacy Compounding Advisory Committee meeting on peptides, emphasizing that the committee's recommendations marked a meaningful step forward for the field but stopped well short of a green light for immediate compounding access.

LaValle explains that the committee recommended six of seven nominated peptides for inclusion on the Section 503A Bulks List, underscoring that FDA retains final authority and that formal rulemaking still lies ahead. He continued to outlined the International Peptide Society's role in evaluating each compound on its own merits rather than defending the category wholesale, warning that a blanket rejection or prolonged regulatory limbo would not eliminate patient demand but would instead push people toward unregulated research-chemical markets.

LaValle also addressed the evidentiary and clinical challenges facing peptide medicine, calling for intellectual honesty about uneven human data while advocating for new infrastructure, including registries, standardized outcome measures, and systematic pharmacovigilance, to build a stronger evidence base.

A transcript of LaValle's conversation with Pharmaceutical Executive can be found below.

Pharmaceutical Executive:The FDA advisory committee meeting on peptides was a defining moment for the field. As Chair of the International Peptide Society, what outcomes from that meeting that were you most concerned about?
James LaValle: The Pharmacy Compounding Advisory Committee recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the Section 503A Bulks List, while Emideltide/DSIP was not recommended. That was an important advisory outcome, but it was not FDA approval, did not immediately change the substances’ legal status and did not itself authorize pharmacies to begin compounding them. FDA retains final authority, and additions to the 503A Bulks List are ordinarily made through notice-and-comment rulemaking.

As Chair of the International Peptide Society, my responsibility is not to defend every peptide or every claim being made about peptides. It is to advocate for a framework that evaluates each compound on its own merits and keeps patient care in the most accountable channel possible.

The two outcomes I was most concerned about were a blanket rejection of the entire category and a prolonged period of regulatory inaction. Peptides are not one homogeneous group. Each molecule, chemical form, route of administration and proposed clinical use needs to be evaluated independently. The committee’s decision to recommend six of the seven substances demonstrated that it was willing to make those distinctions rather than issue a categorical “no.”

A blanket rejection would not eliminate patient demand. It would foreclose the pathway toward regulated access and push more patients toward research-chemical websites and other gray-market sources where product identity, potency, sterility, storage conditions, and accountability may be uncertain. That concern was expressed directly during the hearing: several favorable votes were based partly on the belief that supervised pharmacy access would be safer than leaving patients to obtain these substances outside the healthcare system.

The second potential harm is regulatory limbo. A favorable advisory recommendation without timely final action leaves responsible clinicians and pharmacies constrained while the unregulated market continues operating. My position is not access without standards. It is access through qualified clinicians and licensed pharmacies, with appropriate patient selection, informed consent, quality controls, monitoring, and follow-up. The safest answer is not to drive the market underground.

PE: How do you make the case for clinical utility when the data infrastructure was never built to satisfy that standard?
LaValle: The first step is intellectual honesty. The evidence is uneven and, for several of these compounds, human data remain limited. Clinical utility cannot be established through social-media enthusiasm, testimonials or practitioner anecdotes alone. At the same time, the Section 503A evaluation is not identical to a new-drug approval review. FDA established specific criteria for evaluating nominated bulk substances and applies a balancing assessment on a substance-by-substance basis. It is a different regulatory question from whether a sponsor has submitted the complete evidence package required for FDA approval.

The appropriate case for clinical utility is made through evidence triangulation: clear chemical identity and characterization, nonclinical evidence, available human literature, historical clinical experience, biologic plausibility, documented patient outcomes and an honest review of adverse-event signals. None of those elements should be exaggerated, but none should be dismissed simply because a traditional pharmaceutical development program was never built around the molecule.

We also have to create the infrastructure that has been missing. That means prospective registries, standardized definitions of clinical indications and treatment response, lot-level traceability, validated outcome measures, systematic adverse-event reporting and pragmatic clinical research conducted in real-world settings.

You do not solve a data gap by driving care into a market that captures no data. The responsible approach is to acknowledge uncertainty, establish controlled clinical pathways and use those pathways to generate better evidence. Compounding should never be presented as a substitute for FDA approval, but regulated clinical access can become part of a learning system rather than an evidence-free environment.

PE: What is your assessment of what came out of FDA’s meeting, and what does the compounding world look like now on the other side of it?
LaValle: Now that the meeting has occurred, the result was more favorable to patient access than many anticipated, but the field did not receive a blank check. The committee recommended six of the seven peptides, while Emideltide was the only substance not recommended. Several of the votes were closely divided, which reflects both the potential clinical interest and the legitimate concern about gaps in characterization, safety, and effectiveness data.

While the immediate compounding world did not change overnight, the strategic landscape did. Nothing discussed at the hearing became FDA approved, and the committee’s recommendation did not automatically authorize compounding. FDA still can accept or reject the recommendations, and the agency also has to complete the applicable regulatory process before the substances can be added to the 503A Bulks List.

On the other side of this, I expect the market to divide into two very different segments. The responsible segment will move toward stronger product specifications, supplier qualification, better clinical documentation, patient-selection criteria, outcome tracking and pharmacovigilance. The irresponsible segment will misuse phrases such as “FDA approved,” overstate what the committee decided and continue marketing products through poorly controlled channels.

If FDA follows the recommendations and establishes workable guardrails, appropriate patient-specific care could move into a more accountable physician-pharmacy model. If final action is delayed indefinitely or the recommendations are ultimately rejected, patient demand will not simply disappear. Much of it will migrate toward the least transparent and least accountable portion of the market. Regulators have to consider that practical public-health consequence alongside the evidentiary questions.

PE: How do you respond to critics who argue that peptide protocols lack the standardization needed to be practiced safely at scale?
LaValle: Critics are correct that peptide medicine needs stronger standardization. Where I disagree is with the assumption that individualized medicine and standardization are opposites. Individualized does not mean arbitrary. You standardize the clinical process and the safety architecture; you individualize the decision based on the patient.

Any peptide protocol practiced responsibly at scale should have defined standards for product identity and quality, route of administration, proposed indication, inclusion and exclusion criteria, contraindications, baseline assessment, informed consent, dosing and titration parameters, monitoring intervals, stop rules, medication-interaction review, documentation and adverse-event reporting.

The hearing itself demonstrated why that specificity matters, as the committee did not vote on “peptides” as one interchangeable category, rather it evaluated individual molecules, separate free-base and acetate forms and defined proposed uses. That is how the clinical field should approach them as well.

From a Metabolic Code perspective, the peptide is never the assessment. The assessment comes first. A clinician should understand the patient’s metabolic status, medications, body composition, sleep, nutritional status, inflammatory burden, organ function, goals and risk profile before considering whether a peptide has any appropriate role.

A peptide should not substitute for nutrition, exercise, sleep, recovery or appropriate medical care. It should also never become an excuse to stack multiple compounds without a defined rationale or measurable objective. Safe scale comes from reproducible systems, measured outcomes and clear accountability not cookbook prescribing, but also not improvisation.

PE: Are peptides on a trajectory toward mainstream pharmaceutical development and FDA approval, or is the regulatory environment more likely to push this field further underground?
LaValle: The broader peptide modality is not inherently fringe. The question is whether these specific, currently unapproved molecules will move through conventional pharmaceutical development.

For any individual compound to obtain FDA approval, a sponsor must fund chemical and manufacturing development, dose-finding studies, controlled clinical trials, and a formal regulatory application. Some peptides may eventually make that transition, while others may not due to the evidence failing to support development or because the intellectual-property and economic incentives don’t support the cost of a traditional drug-development program.

The regulatory environment can either create a bridge toward stronger evidence or push demand further underground. A prohibition-only approach does not erase consumer interest. It can shift access toward offshore suppliers and research-chemical vendors operating outside normal clinical safeguards. A workable pathway could keep appropriate patient-specific use inside licensed healthcare while registries, pharmacovigilance programs, and formal trials improve the evidence base.

The committee’s six favorable recommendations suggest that a regulated middle path remains possible, but those votes must never be confused with FDA approval.

My expectation is that a relatively small number of peptides will ultimately enter mainstream pharmaceutical development, many exaggerated claims will fall away under scientific scrutiny, and some compounds may remain within a tightly governed patient-specific compounding pathway. The public-health objective should be straightforward: make the regulated, supervised pathway safer and more attractive than the underground one.